e16416 Background: Pancreatic cancer (PC) incidence continues to increase globally. Early-onset PC (eoPC), defined variably as PC diagnosed 1 yr with stable disease, and 3 others with gBRCA1/2 PVs on PARP +/- IO therapy (POLO and TAPUR trials), one pt achieving CR. Notably, 1 patient with a MSI-H eoPC (germline negative) achieved disease control for > 30 months on single-agent IO. Conclusions: Early onset pancreatic cancer represents a unique subset of PC with rising incidence and distinct molecular patterns. Younger patients are more likely to harbor germline mutations and KRAS wild-type tumors and as targeted therapies continue to expand, early and comprehensive genetic testing will be increasingly critical to guide treatment decisions and improve outcomes for these patients.
Namjoshi et al. (Thu,) studied this question.